Metformin and cancer: active surveillance needed
Key claim: Attia argues that metformin has failed in prostate cancer and many other cancers, and that rare exceptions require precision and active surveillance rather than blanket longevity or oncology assumptions.
Abstract
Metformin failed in prostate cancer and many others—but exceptions remind us to think with precision about interventions The post Metformin and cancer: active surveillance needed appeared first on Peter Attia MD.
Why this matters
Attia argues that metformin has failed in prostate cancer and many other cancers, and that rare exceptions require precision and active surveillance rather than blanket longevity or oncology assumptions.